Apolipoprotein E (ApoE) is mainly secreted by glial cells and is involved in many brain functions, including neuronal plasticity, A-amyloid clearance, and neuroprotection. MicrogliaVthe main immune cells of the brainVare one source of ApoE, but little is known about the physiologic regulation of microglial ApoE secretion by neurons and whether this release changes under inflammatory or neurodegenerative conditions. Using rat primary neural cell cultures, we show that microglia release ApoE through a Golgi-mediated secretion pathway and that ApoE progressively accumulates in neuroprotective microgliaconditioned medium. This constitutive ApoE release is negatively affected by microglial activation both with lipopolysaccharide and with ATP. Microglial ApoE release is stimulated by neuron-conditioned media and under coculture conditions. Neuron-stimulated microglial ApoE release is mediated by serine and glutamate through N-methyl-Daspartate receptors and is differently regulated by activation states (i.e. lipopolysaccharide vs ATP) and by 6-hydroxydopamine. Microglial ApoE silencing abrogated protection of cerebellar granule neurons against 6-hydroxydopamine toxicity in cocultures, indicating that microglial ApoE release is neuroprotective. Our findings shed light on the reciprocal cross-talk between neurons and microglia that is crucial for normal brain functions. They also open the way for the identification of possible pharmacologic targets that can modulate neuroprotective microglial ApoE release under pathologic conditions.
INTRODUCTION
Apolipoprotein E (ApoE) is a 34-kDa glycosylated protein that was originally identified for its involvement in cholesterol transport (1) . It also plays an important role in human neurologic disorders, mainly Alzheimer disease (AD) and cerebral amyloid angiopathy, and in acute brain injury, by negatively affecting insult outcome (1Y4). Apolipoprotein E is the main apolipoprotein in the CNS (4, 5) , and multiple functions have been ascribed to it. For example, ApoE is involved in neurite outgrowth and neuronal plasticity (6) , and it regulates A-amyloid structure, clearance, and neurotoxicity (7Y9). Apolipoprotein E and ApoE-mimetic peptides exert neuroprotective effects, whereas ApoE fragments (10) protect neurons from excitotoxic insults, oxidative stress, and A-amyloid toxicity, and promote antiapoptotic signaling in vitro (7, 11Y13) . Both ApoE and ApoE-derived peptides have shown neuroprotective properties in animal models of cerebral hemorrhage, traumatic head injury, and AD, mainly through downregulation of the inflammatory response associated with microglial activation (3, 5, 9, 14) .
Microglia are an important source of ApoE. This protein is synthesized and secreted by microglial cell lines (15, 16) and by primary microglia (8, 17, 18) . Secreted ApoE is involved in neuroprotection against A-amyloid neurotoxicity mediated by microglia-conditioned medium (MCM) (8) . Although the modulation of ApoE secretion by microglia seems to be crucial for its rapid regulation in the CNS, little is known about the physiologic regulation of microglial ApoE secretion by neuronal stimuli and how this regulation may be modified under inflammatory and neurodegenerative conditions. Therefore, using neuron-conditioned media and neuron-microglia cocultures, we investigated ApoE release by microglia and how this may be regulated by neurons under pathophysiologic conditions. We previously established the neuroprotective role of MCM against various neurotoxic insults delivered to cerebellar granule neurons (CGNs) (19Y21)Vone of the most widely used models for the study of neuron survival and death (22) . Moreover, by proteomic analysis of MCM, we also detected a prominent protein spot that was subsequently identified as ApoE by mass spectrometry. Here, we investigated the microglial release of ApoE and, in particular, its regulation by neuronal cells in in vitro models of brain pathophysiology. Furthermore, we used our model systems of neuron-microglia interaction to gain insight into the specific contribution of ApoE to neuroprotection elicited by MCM.
Italy, Udine, Italy), as previously described (19) . All animal experiments were authorized by the University of Bologna bioethical committee (protocol no. 17-72-2012 ) and performed according to Italian and European Community laws on animal use for experimental purposes. Briefly, brain tissue was separated from meninges and trypsinized for 15 minutes at 37-C; after mechanical dissociation, the cell suspension was seeded on 75-cm 2 flasks coated with 10 Kg/mL of poly-L-lysine (SigmaAldrich, St Louis, MO). Mixed glial cells were cultured for 7 to 8 days in basal medium Eagle (BME; Life Technologies Italia, Monza, Italy) supplemented with 10% heat-inactivated fetal bovine serum (Life Technologies Italia), 2 mmol/L of gluta mine, and 100 Kmol/L of gentamicin sulfate (Sigma-Aldrich Srl, Milan, Italy). Microglial cells were harvested from mixed glial cultures by mechanical shaking, resuspended in serum-free BME, and plated on uncoated 35-mm K dishes (1.5 Â 10 6 cells/ 1.5 mL of medium per well). Cells were allowed to adhere for 30 minutes and washed to remove nonadhering cells. These primary cultures are pure microglial cells; more than 99.5% of adherent cells are positive for isolectin B 4 and negative for astrocyte and oligodendrocyte markers, as previously demonstrated (23) and as confirmed under our culture conditions (data not shown). Microglial cells were exposed to brefeldin A (BFA), lipopolysaccharide (LPS), or 2 ¶-3 ¶-O-(4-benzoylbenzoyl)-ATP (Bz-ATP); serine or glutamate; serine and glutamate; or serine with MK-801 or 6-hydroxydopamine (6-OHDA; Sigma-Aldrich). After different conditioning times, MCM were collected, filtered through 0.22-Km filters, and stored at j20-C until used or desalted and concentrated using Microcon YM-3 (Millipore, Billerica, MA), with a 3-kDa cutoff for Western blot analysis. Microglial cells were collected in 2Â loading buffer (LB; 50 KL per dish). For immunocytochemistry, the cells were fixed with 4% paraformaldehyde (PFA) in phosphate buffer at room temperature for 20 minutes and washed in phosphate-buffered saline (PBS).
CGNs and CGN-Conditioned Medium
Primary CGN cultures were prepared from 7-day-old Wistar rats, as previously described (19) . Briefly, cells were dissociated from cerebella and plated on 96-well plates or 35-mm K dishes previously coated with 10 Kg/mL of poly-Llysine (0.12 Â 10 6 and 2.4 Â 10 6 cells/well, respectively) in BME with 10% heat-inactivated fetal bovine serum (Life Technologies Italia), 2 mmol/L of glutamine, 100 Kmol/L of gentamicin sulfate, and 25 mmol/L of KCl (Sigma-Aldrich). Sixteen hours later, 10 Kmol/L of cytosine arabinofuranoside (Sigma-Aldrich) was added to avoid glial proliferation, leading to less than 2% glial contamination (almost astrocytes; data not shown) (19) . After 7 days in vitro, differentiated neurons were shifted to serum-free medium with or without 20 Kmol/L of 6-OHDA, 100 Kmol/L of glutamate, or 5 mmol/L of KCl (Sigma-Aldrich). The neuroprotective effect of MCM and exogenous ApoE (human ApoE3; Biovision Inc, Milpitas, CA) was tested by cotreating control and 6-OHDA (20 Kmol/ L)Ytreated CGNs with either MCM or increasing doses (100Y500 nmol/L) of exogenous ApoE added to the nonprotective MCM fraction less than 3 kDa (20) . Neuron survival was analyzed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay or nuclei counting after Hoechst staining.
For microglia treatment and Western blot analysis, CGNconditioned medium (cgNCM) was collected for 24 hours, as previously described for MCM.
Microglia-CGN Cocultures
For microglia-CGN cocultures, 3 different systems were used. First, microglia exposed to cgNCM were conditioned for 24 hours by differentiated CGNs (2.4 Â 10 6 cells/mL of medium per well in 35-mm K dishes at 7 days in vitro) in serumfree BME at 25 mmol/L of KCl with or without 20 Kmol/L of 6-OHDA. All media were used to treat microglial cells (1.5 Â 10 6 cells/mL of medium per well in 35-mm K dishes) under control conditions (BME; 25 mmol/L of KCl) for 24 hours and with BFA for 4 hours, 100 ng/mL of LPS for 24 hours, 20 Kmol/L of Bz-ATP for 4 hours, or 200 Kmol/L of MK-801 for 24 hours. Media conditioned by microglia in the presence of cgNCM under different experimental conditions were collected, stored at j20-C, concentrated as previously described, and used for Western blot analysis.
For CGNs exposed to MCM, the medium was conditioned for 24 hours by microglial cells in serum-free BME at 5 mmol/L of KCl 5 (1.5 Â 10 6 cells/mL of medium per well in 35-mm K dishes) and used at 25 mmol/L of KCl to treat differentiated CGNs (0.12 Â 10 6 cells/well on 96-well plates at 7 days in vitro) with or without 20 Kmol/L of 6-OHDA for 24 hours for MTT assay.
For CGN-microglia cocultures, microglial cells (1.5 Â 10 6 ) were plated on differentiated CGNs (2.4 Â 10 6 cells/well in 35-mm K dishes at 7 days in vitro) in the same medium (1 mL of serum-free BME at 25 mmol/L of KCl) with or without 20 Kmol/L of 6-OHDA for 24 hours. Conditioned media were collected and stored at j20-C until used. For Western blot analyses, cells were collected in 2Â LB (100 KL per dish). For immunofluorescence, cells were fixed with 4% PFA for 20 minutes.
Real-Time Polymerase Chain Reaction
Apolipoprotein E messenger RNA (mRNA) expression was quantified in microglia and astrocytes. For total RNA extraction, 2 Â 10 6 cells were directly lysed in 1 mL of Tri reagent (Sigma-Aldrich), according to the manufacturer's protocol. RNA pellets were resuspended in deionized water treated with diethyl pyrocarbonate (Sigma-Aldrich). RNA levels were quantified using a NanoDrop UV spectrophotometer (NanoDrop Products; Thermo Scientific, Wilmington, DE) and stored at j80-C until used for complementary DNA synthesis. For each sample, 1 Kg of DNase-treated RNA (Fermentas, Burlington, Canada) was retrotranscribed using the Superscript III FirstStrand Synthesis SuperMix for quantitative real-time polymerase chain reaction (RT-PCR) kit (Life Technologies Italia) following the manufacturer's protocol. Complementary DNA was stored at j20-C until used for quantitative RT-PCR.
Rat ApoE (accession number NM_001270681. 
ApoE Enzyme-Linked Immunosorbent Assay
Apolipoprotein E levels in the neuroprotective 48-hour MCM (48h-MCM) were measured using an enzyme-linked immunosorbent assay kit specific for rat ApoE (MyBioSource, San Diego, CA), using the protocol provided by the manufacturer.
High-Performance Liquid Chromatography Analysis
Serine and glutamate levels were determined by highperformance liquid chromatography on a Beckman System Gold apparatus after o-phthalaldehyde precolumn derivatization, as previously described (24) . Briefly, amino acids were separated on a Beckman Coulter ultrasphere reverse-phase C18 column (particle size, 5 Km; length, 25 cm; i.d., 4.6 mm) concurrently with a gradient elution (A, 50 mmol/L of 80% sodium phosphate buffer [pH 6.8] containing 19% methanol and 1% tetrahydrofuran; B, 80% methanol and 20% methanol) and revealed by a Varian LC 9070 fluorescence detector (excitation wavelength, 350 nm; emission wavelength, 450 nm). Data were based on peak area and calibration response curve with standard solutions.
Microglial Small Interfering RNA Transfection
To silence ApoE expression in CGN-microglia cocultures, we transfected microglial cells with commercially available small interfering RNA (siRNA) against rat ApoE (previously tested for efficacy by the Rosetta bioinformatics system) or with a universal siRNA negative control (Sigma-Aldrich). Microglial cells were transfected in a suspension using LipofectAMINE 2000 Reagent in OptiMEM/serum-free BME (all from Life Technologies Italia) without antibiotics, following the manufacturer's protocol, and immediately plated on differentiated CGNs in 35-mm K dishes. The medium with the LipofectAMINE-DNA complex was replaced with serum-free BME. Twenty-four hours after siRNA transfection, cocultures were exposed to 20 Kmol/L of 6-OHDA for an additional 24 hours. For Hoechst staining and immunocytochemistry, cells were fixed with 4% PFA for 20 minutes. For ApoE silencing in rat primary microglia, cells were transfected as described previously; after 4 hours, the medium with the LipofectAMINE-DNA complex was replaced with serum-free BME. Twenty-four or 48 hours after siRNA transfection, MCM were collected, cleared of contaminating cells by filtration (with 0.22-Km filters) or centrifugation (10,000 Â g for 5 minutes), and stored at j20-C until used for Western blot analysis.
For analysis of ApoE release, 500 KL or 1 mL of conditioned media from pure microglial cell cultures and cocultures was desalted and concentrated using Amicon YM-3 centrifugal filters (Millipore) 
Viability Assays
Viability of CGNs in culture was evaluated by MTT assay and nuclei counting after Hoechst staining (19Y21).
For MTT assay, thiazolyl blue was added to a culture medium at a final concentration of 0.1 mg/mL. After a 20-minute incubation at 37-C in the dark, the MTT precipitate was dissolved in 0.1 mol/L of Tris-HCl buffer containing 5% Triton X-100 (all from Sigma-Aldrich), and absorbance at 570 nm was read by a Multiplate Spectophotometric Reader (Bio-Rad Laboratories Srl).
For nuclei counting after Hoechst staining, CGNs or CGN-microglia cocultures were fixed with 4% PFA in phosphate buffer for 20 minutes, washed in PBS, and incubated with 0.1 Kg/mL of Hoechst 33258 (Sigma-Aldrich) for 5 minutes at room temperature. Cultures were observed and photographed with a fluorescence microscope (20Â objective), and counting was performed on 5 randomly selected fields from each 35-mm K dish. Neuronal survival was evaluated by counting normal uncondensed nuclei (size between 4.2 and 4.8 Km), as previously described (25) . Under this staining condition (5 minutes of incubation), Hoechst hardly stained microglial nuclei, which usually require at least 20 minutes of incubation, whereas CGN nuclei stained. Microglial nuclei that occasionally stained can be excluded from counting because they are oval (not rounded as CGN nuclei) and considerably larger.
Immunocytochemistry
Control microglial cells treated with BFA for 4 hours and cocultures treated or not treated with 20 Kmol/L of 6-OHDA for 24 hours were fixed with 4% PFA, washed with PBS, and permeabilized with 0.1% Triton X-100/PBS. Nonspecific sites were blocked with 5% normal goat serum in 0.1% Triton X-100/PBS (all chemicals from Sigma-Aldrich) for 1 hour at room temperature. After several washes, cells were incubated overnight at 4-C with rabbit anti-ApoE antibody (Santa Cruz Biotechnology Inc), mouse anti-GM130 antibody (Santa Cruz Biotechnology Inc), and secondary antibodies (anti-rabbit fluorescein isothiocyanate [FITC] and anti-mouse tetramethylrhodamine-isothiocyanate [TRITC]; Sigma-Aldrich) for 1.5 hours at room temperature. Nuclei were stained with Hoechst 33258 (0.1 mg/mL; Sigma-Aldrich) for 5 minutes at room temperature. Control staining was performed using normal rabbit IgG or normal mouse IgG (Santa Cruz Biotechnology Inc) of primary rabbit or primary mouse antibodies, respectively; this yielded no labeling (data not shown). For isolectin B 4 microglial staining, cocultures were preincubated with biotin-labeled isolectin B 4 and FITC-labeled ExtrAvidin (Sigma-Aldrich), whereas ApoE staining was performed using rabbit anti-ApoE antibody (Santa Cruz Biotechnology Inc) and anti-rabbit TRITC antibody (Sigma-Aldrich). In this case, control staining was performed, respectively, with FITC-labeled ExtrAvidin (Sigma-Aldrich) only or with normal rabbit Ig followed by anti-rabbit TRITC antibody (Sigma-Aldrich), giving no signals (data not shown). Stained cultures were mounted with Vectashield fluorescence mounting media (Vector Laboratories Inc, Burlingame, CA) observed with a fluorescence microscope (Eclipse TE 2000-S microscope; Nikon, Tokyo, Japan). Images were acquired with an AxioCam MRm digital camera (Zeiss, Oberkochen, Germany).
Statistical Analysis
All results were subjected to statistical analysis with Student t-test or 1-way (or 2-way) analysis of variance followed by Bonferroni post hoc test, using GraphPad Prism 4 software to evaluate the significance of differences.
RESULTS

Microglia Constitutively Release ApoE Through the Golgi Pathway
We have previously demonstrated that rat primary microglial cells release factors that protect CGNs exposed to various neurodegenerative stimuli (19Y21). Using a proteomics approach, we identified several protein spots in MCM samples, among which ApoE was one of the most often expressed, together with 19-and 17-kDa ApoE fragments, suggesting its proteolytic fragmentation (21) . To characterize the time course of ApoE release by microglial cells, we performed Western blot analysis of different MCM. We observed that microglia constitutively secreted ApoE, which progressively accumulated in the medium (being detectable after 2 hours), increased from 8 to 12 hours, and peaked from 24 to 48 hours of microglial conditioning (no significant difference between 24 and 48 hours; Fig. 1A ). At later time points (i.e. 72 hours), we observed a decrease in ApoE release that could be caused by a decrease in microglia viability because these secondary cultures have limited lifetimes. We used PNPVan enzyme known to be released by microglial cells (our unpublished data)Vas reference protein for loading control in the same medium (Figs. 1A, B) . In only a few cases did Western blot analysis reveal traces of the 19-kDa ApoE fragment (data not shown). We performed ELISA to quantify the amount of ApoE secreted in neuroprotective 48h-MCM, and the mean T SE ApoE concentration in 48h-MCM was estimated to be 9.3 T 1.82 pmol/mL. Because of contrasting results for microglial expression of ApoE (although it has been clearly demonstrated that astrocytes produce ApoE [8, 15Y18] ), we performed RT-PCR of microglial cell cultures with astrocyte culture as control to demonstrate microglial ApoE expression under our experimental conditions. As shown in the Table 1 , microglial cells express 5 times more ApoE mRNA than do astrocytes in our cell cultures, in which astrocytic contamination is less than 0.5%, thus confirming that ApoE is largely produced by microglial cells.
Constitutive ApoE secretion occurs through the classical endoplasmic reticulum/GolgiYdependent secretory pathway in macrophages and astrocytes (26, 27) ; therefore, we investigated whether this pathway was also involved in microglial ApoE secretion. We exposed microglial cells to BFA, an inhibitor of Golgi-dependent protein secretion, which acts by disassembling this apparatus (28) . Treatment of microglia with 5 Kg/mL of BFA for 4 hours resulted in complete absence of ApoE in MCM, as revealed by Western blot analysis and relative densitometries, whereas PNP release was not affected (Figs. 1C, E) . The near-complete absence of ApoE in BFA-treated 4-hour MCM was caused by blocked release and not by synthesis interference because ApoE accumulated in corresponding cellular lysates (Figs. 1D, F) , clearly suggesting intracellular retention of synthesized ApoE protein.
Confirmatory evidence was derived from immunofluorescence experiments, in which microglial cells were stained for ApoE (green fluorescence) and for the Golgi marker GM130 (red fluorescence; Fig. 1G ). Under control conditions, ApoE immunoreactivity showed supranuclear localization that colocalized with GM130 staining, corresponding to normal configuration of Golgi apparatus; in BFA-stimulated cells, ApoE and GM130 staining were widespread, indicating Golgi disorganization and dispersion throughout the cytoplasm (Fig. 1G) .
Modulation of Microglial ApoE Secretion by Activation
We tested whether constitutive release of ApoE by microglia was altered under different conditions of activation, a common occurrence in various types of CNS pathology (29, 30) . Microglial stimulation for 24 hours with increasing concentrations of the most commonly used microglial activator LPS (10Y1,000 ng/mL) significantly decreased ApoE levels, but not PNP, in the medium (Figs. 2A, C) and in cell lysates (Figs. 2B, D) , confirming negative regulation of both ApoE synthesis and release by microglial activation, as previously reported (17, 18) .
We also tested whether activation of the P 2 X 7 receptor (a glial activator stimulus associated with cellular damage and chronic brain inflammation more physiologic than LPS [31, 32] ) could negatively modulate ApoE release, with a final effect on ApoE accumulation in the medium similar to that of LPS itself but through a different mechanism. The P 2 X 7 receptor is a member of the purinergic P 2 X family of ATP-gated ion channels, and high levels of extracellular ATP are required for its rapid activation. As with LPS, stimulation with increasing concentrations (50Y200 Kmol/L) of benzoyl-ATP (a specific agonist of the P 2 X 7 receptor that is more stable than ATP) for 4 hours resulted in a significant reduction of released ApoEVbut not of PNP (Figs. 2E, G)Vwithout any significant effect on intracellular ApoE levels (Figs. 2F, H) . Therefore, although the decrease in ApoE release caused by LPS could be mediated by negative regulation of its synthesis (17, 18) , the one induced by P 2 X 7 receptor activation seems most probably regulated only at the release level. The lack of Bz-ATP effect on ApoE synthesis could be tested only for the relatively short time of treatment because longer exposures are toxic for microglia The treatments used here have been previously demonstrated to be effective in activating microglia without affecting their survival (33, 34) .
Neuronal Induction of Microglial ApoE Release
It is well known that neurons influence microglial activation states and the microglial secretory pathway (34Y36). We therefore decided to study whether neurons could modulate microglial ApoE release under unstimulated or activated conditions. To this aim, we decided to use cerebellar granule cells as a neuronal model; it has previously been demonstrated that these neurons do not express ApoE (37, 38) . We treated microglial cells for 24 hours with a medium previously conditioned for 24 hours by mature CGNs (cgNCM) and tested ApoE release from neuron-stimulated microglia through Western blot analysis. The cgNCM induced much higher ApoE but not PNP release levels from microglia compared with the control medium (Figs. 3A, B) . Increased ApoE accumulation was not caused by neuronal release because Western blot analysis did not detect any ApoE in control cgNCM (Figs. 3A, B) . This suggests that CGNs release a factor (or factors) in the medium that stimulates additional ApoE release from microglia. Neuron-stimulated microglial ApoE release seemed to involve the same intracellular constitutive Golgi-dependent pathway because 5 Kg/mL of BFA blocked ApoE accumulation in the medium from microglia exposed to 24-hour cgNCM (24h-cgNCM) for 4 hours (Figs. 3C, D) . Moreover, different states of microglial activation (i.e. stimulated by LPS or Bz-ATP) differently regulated microglial ApoE release induced by 24h-cgNCM. In fact, LPS treatment (100 ng/mL) for 24 hours decreased ApoE microglial release induced by 24h-cgNCM (Figs. 3E, F) , similarly to pure microglial cultures. On the other hand, activation of microglial P 2 X 7 receptor by 4-hour stimulation with 100 Kmol/L of Bz-ATP did not result in any significant reduction of microglia-ApoE release induced by 24h-cgNCM (Figs. 3G, H) , suggesting the existence of a delicate regulatory balance for microglial ApoE secretion from different microglia-activating stimuli under conditions of neuronal stimulation.
Serine has been previously demonstrated to induce microglial ApoE release (18) . This amino acid is released by neurons and plays an important role as gliotransmitter and in regulating neuronal survival/death (39, 40) . Therefore, we decided to measure the 24h-cgNCM content of serine through high-performance liquid chromatography analysis; it was determined to be 12.2 Kmol/L in concentration, with no significant change in the presence of 200 Kmol/L of MK-801 (12.8 Kmol/L). We evaluated whether serine released by CGNs could be involved in neuronal induction of microglial ApoE release. To this aim, we treated primary cultures of rat microglial cells with increasing concentrations (1, 10, 50, and 100 Kmol/L) of serine 
Neuronal Modulation of Microglial ApoE Secretion Under Neurodegenerative Conditions
To explore differences in the neuronal stimulation of microglial ApoE release not only under physiologic conditions but also under pathologic conditions, we compared ApoE release from microglia treated with a medium conditioned for 24 hours by CGNs exposed to 20 Kmol/L of 6-OHDA (24h-cgNCM + 6-OH) or under control conditions (24h-cgNCM). Previous data showed that exposure to 6-OHDA resulted in extensive degeneration of CGNs through apoptosis (20, 21, 43Y45) (MTT assay and Hoechst staining in Fig. 5 ). A medium conditioned by CGNs exposed to 6-OHDA exerted a stimulatory effect on microglial ApoE release very similarly to that of the medium from healthy neurons, thus indicating that there is no difference attributable to impaired viability or function of neurons or to an effect of the neurotoxin on mi croglia viability (Figs. 6A, B) . In fact, 20 Kmol/L of 6-OHDA exposure for 24 hours does not induce any toxic effect on microglial cells and does not alter the release of ApoE or its subcellular localization in microglial cell cultures (data not shown). Interestingly, microglial ApoE release induction very similar to what was obtained by a medium conditioned by CGNs exposed to 6-OHDA (176% T 15% vs 100% of 24h-MCM) was also achieved by other neurodegenerative stimuli, for example, 24-hour exposure to 100 Kmol/L of glutamate and 5 mmol/L of potassium (195% T 14% and 190% T 16% ApoE release, respectively). This further demonstrates that neurodegenerative conditions do not seem to alter the induction of microglial ApoE release by neuron-conditioned medium in vitro.
We also used cocultures of microglia with neurons to investigate reciprocal interactions between these cell types, which may be mediated not only by exchange of released molecular signals but also by physical cell contact (19, 20) . Therefore, we studied cocultures of primary microglia and CGNs under physiologic conditions and in the presence of 20 Kmol/L of 6-OHDA. We observed a strong induction of microglial ApoE release in cocultures with healthy CGNs (24h-MCM + 24h-cgNCM; Figs. 6C, D), thus confirming previous results obtained with 24h-cgNCM. On the other hand, there was a significant decrease in microglial ApoE release when cocultures were exposed to 20 Kmol/L of 6-OHDA (24h-MCM + 24h-cgNCM + 6-OH; Figs. 6C, D) . Decreased ApoE release could not be attributed to microglial damage because 6-OHDA, by itself, did not affect microglial survival (as shown by immunofluorescence in Fig. 6E ) or to neuronal death because microglia are neuroprotective against CGNs in cocultures, as previously demonstrated (21) and as shown in Figure 6G . However, 6-OHDA treatment did affect ApoE localization in microglia in coculture (Figs. 6F, G) . Immunoreactivity of microglial ApoE in cocultures with CGNs showed a typical localization corresponding to normal configuration of Golgi apparatus, whereas in the presence of 20 Kmol/L of 6-OHDA, microglial ApoE immunostaining was widespread, with Golgi disorganization and dispersion throughout the cytoplasm (Figs. 6F, G) , similar to what was observed after BFA treatment, which leads to decreased microglial ApoE release (Fig. 1D) . This observation could explain the decreased ApoE accumulation in the medium from 6-OHDAYtreated cocultures compared with controls.
Role of ApoE in Microglial Neuroprotection
To demonstrate a role for ApoE in microglia-mediated neuroprotection, we explored the contribution of ApoE to microglial neuroprotection under 2 different culture conditions: CGNs exposed to MCM (thus not in physical contact with microglia) and CGNs in direct contact coculture with icroglia. In both paradigms, we selectively silenced microglial ApoE through siRNA. Microglia completely protected CGNs from 6-OHDA neurotoxicity under both conditions (Figs. 5BYD) , as previously shown also for other neurotoxic challenges (19) . First, we performed experiments to study whether a decrease in ApoE level through microglial silencing in 24h-MCM could reduce its neuroprotective effect. To this aim, we silenced ApoE in microglial cells and collected the medium conditioned by microglia in the first 24 hours (ApoE siRNA 0Y24 hours) or in the second 24-hour period (ApoE siRNA 24Y48 hours) after ApoE silencing. Preliminarily, we observed that ApoE silencing in microglia with specific siRNA resulted in decreased ApoE release, whereas siRNA negative control had no effects (Fig. 5A) . When CGNs were exposed to the abovedescribed ApoE-silenced MCM, both media showed no neuroprotective change toward 6-OHDA (Fig. 5B) . Furthermore, we explored the possibility that ApoE silencing in microglial cells could alter their neuroprotective effect in contact cocultures. We performed cocultures in which 1.5 Â 10 6 cells of microglia were plated on 2.4 Â 10 6 differentiated CGNs after selective microglia ApoE silencing (microglia were transfected in suspension before being plated on CGNs). In these cultures, we performed selective staining of neuronal nuclei with Hoechst and counted healthy uncondensed neuronal nuclei. This protocol allows selective identification and consideration of survival/apoptotic effects on CGNs only (Materials and Methods). Microglial ApoE silencing abrogated the neuroprotection granted to CGNs challenged with neurotoxic 6-OHDA, as demonstrated by normal nuclei counting after Hoechst staining (Figs. 5C, D) . In fact, although control microglia restored CGN survival (101% T 9% of control CGNs), ApoE-silenced microglia did not significantly increase CGN survival (70% T 11% of control CGNs). 6-Hydroxydopamine treatment did not, by itself, induce neuronal expression of ApoE, as immunofluorescence shows that ApoE only colocalizes with the microglial marker lectin B 4 in CGN-microglia cocultures (Fig. 6G) . Therefore, using coculture models with ApoE silencing, we demonstrated that ApoE production from microglia contributes to the neuroprotective action in contact cocultures only.
To confirm ApoE-mediated neuroprotection, we added exogenous ApoE to nonconditioned serum-free medium to observe whether this could, at least in part, replicate the neuroprotective effect of MCM in which ApoE accumulates. To this aim, we exposed mature CGNs (7 days in vitro) for 24 hours to serum-free medium with or without 20 Kmol/L of 6-OHDA and different concentrations of exogenous ApoE (i.e. human recombinant ApoE3), which closely resembles rat ApoE (46) and has been previously shown to be neuroprotective in different neuropathology models (1, 4) . Similarly to MCM, exogenous ApoE3 added to the 48h-MCM fraction less than 3 kDa, which is not neuroprotective by itself (20) , was significantly neuroprotective against 6-OHDA neurotoxicity in a dosedependent way, similar to the complete 48h-MCM (Fig. 5E ).
DISCUSSION
It is well known that microglial cells physiologically express ApoE (47) . This has been confirmed by many in vitro and in vivo studies (8, 17, 18) , although contrasting results have also been reported (47Y49). Recently, in a transgenic mouse that expressed green fluorescent protein in the ApoE gene, approximately 80% of astrocytes expressed ApoE, whereas microglial cells did not express ApoE under normal conditions; less than 10% expressed ApoE after kainic acid treatment (49) . Here, we clearly demonstrate that rat primary microglial cells express ApoE and that it is constitutively released and accumulates in the medium; it represents one of the proteins most abundantly secreted by microglia. Some discrepancy with the in vivo situation may be explained by the fact that isolated cells in vitro may differ in some responses from those in situ, where they interact with other cell types. However, the obvious limitations of the culture condition offer the advantage of identifying specific cellular and molecular mechanisms in a simpler and controlled environment (50) .
The intracellular pathway of ApoE secretion from microglia and whether the secretion of such an important protein in brain pathophysiology is regulated by neurons remain unknown. Microglia represent a ''hybrid'' type of brain cell, sharing characteristics of both neural and immune cells. Similarly to macrophages, microglia possess complex protein secretion machineries, including the classical constitutive endoplasmic reticulum/Golgi pathway and regulated secretion, which involves secretory granules and the lysosomal secretory pathway (26) . Microglia use the lysosome secretory pathway for the release of interleukin-1A and copper/zinc superoxide dismutase through activation of the purinergic P 2 X 7 receptor by ATP (21, 51, 52) . Moreover, like other immune cells, microglia are able to externalize proteins, mRNA, and micro RNA through exosomes and microvesicles, which can be taken up by target cells (53) . We show here for the first time that microglial ApoE release takes place through the Golgi apparatus, as in macrophages (26) . Although constitutive secretion and regulated exocytosis have been traditionally considered quite distinct, in macrophages, ApoE seems to combine constitutive secretion with regulated exocytosis (26, 54) . The same type of secretion was also demonstrated to be involved in ApoE release by rat astrocytes (55) .
Because ApoE is involved in human neurologic disorders, it is important to know what happens to microglial ApoE release under pathologic conditions that may modify microglial protein release (51, 56Y58). Therefore, we studied the effects of activation on microglial ApoE release using 2 activating stimuli. Both LPS and ATP decreased ApoE microglial secretion; the former effect is in agreement with previous data (17, 18) . We show here, as a novel observation, that microglial stimulation through the ATP/P 2 X 7 receptor had a similar effect on ApoE accumulation in the medium, but the effect was through a different mechanism, only affecting release but not synthesis of the protein. Interestingly, whereas LPS stimulation of microglia is considered to mimic inflammation, ATP has been defined as a ''warning molecule'' that represents a less aggressive signal in the neuron-glia cross-talk involved under both physiologic and pathologic conditions (34, 58) . Taken together, our present results suggest that any alteration leading to increased microglial activation results in downregulation of ApoE release. This seems to be in contrast with in vivo data in which microglial activation directly elicited by LPS infusion or induced FIGURE 3. Cerebellar granule neurons further stimulate constitutive ApoE release by microglia; neuron-stimulated microglial ApoE release is differentially downregulated by diverse inflammatory stimuli. Western blot analysis, with PNP as loading control (A), and the corresponding densitometries (B) of media conditioned for 24 hours by control microglia (24h-MCM) and by microglia stimulated with a medium previously conditioned for 24 hours by mature CGNs (24h-MCM/24h-cgNCM) and (as control) with a medium conditioned for 24 hours by mature CGNs (24h-cgNCM). Effects of 4-hour treatment with 0.5 Kg/mL of BFA on neuroninduced microglial ApoE release as shown by Western blot analysis (C) and relative densitometries (D), with PNP as loading control. Effects of microglial activation through 24-hour exposure to 100 ng/mL of LPS on microglial ApoE secretion stimulated by 24h-cgNCM, versus conditioned medium from LPS-untreated neuron-stimulated cells, are shown by Western blot analysis, with PNP staining as loading control (E), and relative densitometries (F). Effects of 4-hour stimulation with 100 Kmol/L of Bz-ATP are shown by Western blot analysis, with PNP staining as loading control (G), and relative densitometries (H). All Western blots are representative analyses of each type of experiment. Each graph bar is expressed as percentage of controls (24h-MCM) and represents the mean T SE of 3 different experiments. ** p G 0.01 versus 24h-MCM in graph B; *** p G 0.001; ** p G 0.01 versus control MCM/24h-cgNCM (Bonferroni test after analysis of variance). by brain injury results in increased ApoE levels (15, 59, 60) . Based on previous results for the downregulation of the microglial inflammatory state by ApoE (3, 5, 14) , we postulate that increased ApoE production from activated microglia is part of an autoregulatory feedback mechanism that controls neuroinflammation in vivo (14, 61) .
We show here that rat primary microglia release ApoE, which progressively accumulates in MCM, and that constitutive ApoE microglial production and release are negatively affected by activation. These data, however, were obtained using a pure microglia in vitro system lacking other brain cells, mainly neurons, which are able to physiologically modulate microglial activation and release of diffusible factors (34Y36). Although astrocytes are known to interact with microglia for modulating ApoE production both in vitro and in vivo (17, 48, 49) , whether and how neurons modulate microglial ApoE release remain to be clarified. In particular, if neuron-glia cross-talk regulates ApoE release, could this be demonstrated by allowing in vitro direct or indirect neuronmicroglia interactions? To answer this question, we used neuron-conditioned media and neuron-microglia cocultures (19Y21). Although these models are far simpler than the in vivo situation, they allow mimicking of actual neuronmicroglia interactions, with good reproducibility (62) . The choice of CGNs for experiments on primary neuronal cultures and neuron-microglia cocultures was dictated by our previous experience with how these neurons respond to the Parkinson diseaseYlinked neurotoxin 6-OHDA, by other death-survival stimuli (these neurons do not express ApoE) (37, 38) , and by an appreciation of the complex relationships between neurons and microglia occurring in conditioned media/coculture experiments (20Y22, 63, 64). We used 2 different approaches: exposure of microglial cells to medium conditioned by mature CGNs for 24 hours and coculture experiments in which microglial cells were directly plated over mature CGNs. We demonstrated for the first time that diffusible signals from healthy neurons stimulate the secretion of ApoE from microglial cells in culture. In particular, we showed that neurons induce microglial ApoE secretion through the release of serine and glutamate, which act on microglial NMDA receptors, thus confirming the role of serine as a gliotransmitter (40, 41) . Serine is acquiring increasing importance in neuron-glia communication. In particular, this amino acid is believed to be an endogenous coagonist for NMDA receptors, modulating synaptic transmission and plasticity mediated by this receptor during development. Moreover, in adult brains, serine is additionally implicated in neurodegeneration and neuroprotection (65) . Interestingly, brain serine is known to be released mainly by neurons (up to 90%), but this neuron-secreted serine can act on neurons themselves and on glial cells (66) , including microglia, which express NMDA receptors on their surface (67, 68) . Although the induction of microglial ApoE release through exogenous serine has been previously demonstrated (18) and confirmed, we have additionally shown that serine and glutamate released by neurons can modulate microglia ApoE release by acting on NMDA receptors, thus strengthening the pathophysiologic role of these molecules in neuron-microglia crosstalk. The role of NMDA receptors in modulating microglial protein release is not surprising because it has been previously demonstrated for microglial release of neurotrophic factors (69) . We have shown that NMDA-mediated microglial protein release is not only caused by glutamate but also modulated by serine, thus adding an additional important role for this gliotransmitter in neurotransmission and neurodegeneration (41, 65, 66) . We also speculate that NMDA activation could positively modulate ApoE release by increasing intracellular calcium concentration because calcium entry induces protein release in microglial cells (70, 71) and by inducing the activation of intracellular protein kinase cascades (69) . A further important observation is that ApoE release induced by cgNCM is differently modulated by microglial activation because microglial stimulation with LPS strongly downregulated neuron-induced secretion of ApoE, whereas ATP-mediated activation through the P 2 X 7 receptor did not.
Moreover, in coculture experiments, we demonstrated that neurons challenged with the neurotoxic stimulus 6-OHDA induce lower microglial ApoE release levels than healthy neurons caused by their impaired viability, whereas microglia are neuroprotective in cocultures under these conditions. We chose 6-OHDA as the neurotoxic stimulus in CGNs as a paradigm of neuronal death caused by oxidative stress. Cerebellar granule neurons are one of the most widely used models of primary cultures for the study of neuronal survival/death mechanisms and pathways. Knowledge acquired in this model may be transferred to many other neuronal types; it may be useful for in vitro approach to different brain pathologies, including AD (22, 63, 64) , and it may be translated into in vivo studies. 6-Hydroxydopamine has been known to induce neuronal death through oxidative stress caused by free radical formation and mitochondria inhibition, which are common neurodegenerative and pathologic mechanisms not only in Parkinson disease but also in AD and other neurodegenerative diseases (72, 73) . Therefore, the results we obtained in this in vitro model of neurotoxicity may be relevant to degenerative conditions in patients and may have translational applications.
Our results seem to be in contrast with in vitro results obtained in mixed neuron-glia cocultures in which neuronal injury induced ApoE release (74) . However, in that study, the presence of astrocytes, which secrete ApoE and induce microglial ApoE secretion (18) , could explain the differences from our results, which were obtained in the absence of astrocytes. A further relevant difference from the in vivo condition is the in vitro lack of myelin breakdown that occurs after in vivo neuronal injury, which results in microglial lipid phagocytosis and subsequently increased ApoE release. Apolipoprotein E is also involved in myelin cholesterol uptake as it is released in large amounts after peripheral and optic nerve degeneration, and a decrease in ApoE release has been implicated in the pathogenesis of multiple sclerosis (74Y78). In macrophages, it has also been demonstrated that cholesterol loading increases ApoE secretion (79) , and this could additionally explain the difference between our in vitro results and previously published in vivo data. An additional possible explanation for reduced ApoE secretion under our conditions could be that ApoE is less concentrated in the medium of microglia-CGN cocultures exposed to 6-OHDA caused by neuronal uptake (80, 81) . Several published data support this hypothesis: injured neurons internalized ApoE secreted by astrocytes in vitro (80, 82) and neurotoxic A-amyloid increased ApoE internalization in cultured neurons (80, 81) . Furthermore, in an in vivo model of brain injury, glial cells increased the expression and release of ApoE, displaying a concomitant increase in intracellular ApoE in degenerating neurons that was likely caused by internalization of released protein (49, 83) . Another explanation could be that, in our coculture experiments, physical interactions of microglia with degenerating neurons induced microglial activation that was able to reduce ApoE secretion. This last hypothesis is also supported by our immunofluorescence results, that is, 6-OHDA treatment in microglia-CGN cocultures caused a change in microglial ApoE staining with protein dispersion and loss of Golgi ApoE localization (Fig. 6F) , which in turn could be related to the decrease in ApoE release.
As mentioned previously, ApoE shows neuroprotective properties in cultured neurons in several neurotoxicity models (7, 11Y13) . In addition, ApoE released by microglia in MCM contributed to neuroprotection against A-amyloid toxicity in mixed neuronal cultures (8) . Here, we have demonstrated ApoE neuroprotection in a characterized population of homogeneous primary neurons (i.e. CGNs) (22) using the neurotoxicity model of exposure to 6-OHDA, which is fully protected by MCM (20, 21) . Indeed, silencing experiments demonstrated that ApoE was a necessary element for microglial neuroprotection of neurons challenged with 6-OHDA only under contact coculture conditions. These results (i.e. ApoE silencing reduces microglial neuroprotection in contact cocultures but does not decrease the effects of 48h-MCM) are only apparently contradictory and could be explained by the fact that other soluble factors contribute to this neuroprotection (including transforming growth factor A2) (20) or that ApoE can more easily exert its neuroprotective effect when microglia and neurons are physically in contact. In addition, this observation is in agreement with results showing the essential role of microglial ApoE production in rescuing neurons from A-amyloidYinduced neuronal death (8) . Our results show that exogenous ApoE (namely, human recombinant ApoE3Vthe human isoform more similar to rat ApoE) confers neuroprotective properties to the 48h-cgNCM non-neuroprotective (20) fraction less than 3 kDa. Although this effect was observed in a range of concentrations higher than the one identified in neuroprotective MCM, this further supports a pivotal role for this molecule in neuroprotection and suggests that ApoE released in the medium probably requires additional cofactors to act in a physiologic way.
In conclusion, using rat primary cultures and coculture systems, we demonstrate here that microglia release ApoE through the constitutive Golgi pathway. This secretion is positively regulated by neurons through serine release, thus supporting the crucial role of this amino acid in neuron-microglia cross-talk. Moreover, microglial activation, a common feature of many neurodegenerative states, downregulates constitutive ApoE release, and the strong activating stimulus provided by LPS is able to decrease neuron-induced ApoE secretion as well. Therefore, we demonstrate here for the first time that neurons can modulate ApoE release from activated microglia. This regulation is dependent on the type and level of activation. Apolipoprotein E is able to counteract specifically 6-OHDAYinduced CGN neurodegeneration, a condition in which neuron-induced microglial ApoE release is decreased in coculture. Therefore, our demonstration that ApoE produced from microglia is an essential neuroprotective molecule and that neurons may finely modulate its production and release is an important step toward the disclosure of neuron-microglia cross-talk, leading to the identification of microglia-derived neuroprotective factors and neuron-derived regulatory molecules. Once completely identified, these molecules may represent a target for glial manipulation aimed at physiologically promoting endogenous neuroprotection in brain diseases.
